RRV-mediated prodrug activator gene therapy combined with alloreactive T cell immunotherapy for malignancies in the CNS

Retroviral replicating vectors (RRV) show intrinsic tropism for actively dividing cells within the immunosuppressed tumor microenvironment, and viral replication significantly enhances transduction efficiency and therapeutic efficacy for cancer gene therapy. RRV-mediated prodrug activator gene therapy is currently being evaluated in clinical trials at multiple centers (www.clinicaltrials.gov, NCT01156584, NCT01470794) with highly encouraging...